Ultime notizie per Fortrea Holdings (NASDAQ:FTRE) Azioni

FORTREA HOLDINGS INC

Fortrea Holdings

Fortrea Holdings is a late-stage contract research organization, or CRO, that provides comprehensive Phase I through IV clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion. Fortrea has 19,000 staff members across 90 countries.

News

Pre-Market Outlook

Markets

Trading Ideas

BEKE

FTRE

MNDY

Scopri i cinque titoli chiave da seguire nel pre-market di oggi, 12 agosto 2024, con focus su risultati e previsioni.

Pre-market: 5 titoli da monitorare oggi, 12 agosto 2024

Fortrea Holdings Inc

Looking into the current session, Danaher Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>) shares are trading at $197.77, after a 0.69% spike. Moreover, over the past month, the stock increased by 2.97%, but in the past year, decreased by 25.98%. Shareholders might be interested in knowing whether the stock is undervalued, even if the company is performing up to par in the current session. 

<img src="https://www.benzinga.com/files/images/story/2025/1747778422_0.png" alt="Past Year Chart" />

<h3>A Look at Danaher P/E Relative to Its Competitors</h3>
The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E could indicate that shareholders do not expect the stock to perform better in the future or it could mean that the company is undervalued. 
Danaher has a lower P/E than the aggregate P/E of 44.52 of the Life Sciences Tools &amp; Services industry. Ideally, one might believe that the stock might perform worse than its peers, but it's also probable that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2025/1747778422_1.png" alt="Guage" />

In conclusion, the price-to-earnings ratio is a useful metric for analyzing a company's market performance, but it has its limitations. While a lower P/E can indicate that a company is undervalued, it can also suggest that shareholders do not expect future growth. Additionally, the P/E ratio should not be used in isolation, as other factors such as industry trends and business cycles can also impact a company's stock price. Therefore, investors should use the P/E ratio in conjunction with other financial metrics and qualitative analysis to make informed investment decisions.

Intraday Update

P/E Ratio Insights for Danaher

Cigna Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>) has outperformed the market over the past 20 years by 3.82% on an annualized basis producing an average annual return of 12.12%. Currently, Cigna Group has a market capitalization of $88.11 billion. 
Buying $100 In CI: If an investor had bought $100 of CI stock 20 years ago, it would be worth $987.54 today based on a price of $325.00 for CI at the time of writing.
<h3>Cigna Group's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747778415_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning Cigna Group Stock In The Last 20 Years

Borealis Foods (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRLS#NASDAQ">BRLS</a>) reported quarterly losses of $(0.20) per share. This is a 59.18 percent increase over losses of $(0.49) per share from the same period last year. The company reported $6.85 million in sales this quarter. This is a 13.29 percent decrease over sales of $7.89 million the same period last year.

Earnings

BRLS

Borealis Foods Q1 EPS $(0.20) Up From $(0.49) YoY, Sales $6.85M Down From $7.89M YoY

Greenwich LifeSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLSI#NASDAQ">GLSI</a>) reported quarterly losses of $(0.25) per share. This is a 31.58 percent decrease over losses of $(0.19) per share from the same period last year.

GLSI

Greenwich LifeSciences Q1 EPS $(0.25) Down From $(0.19) YoY

ASP Isotopes (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASPI#NASDAQ">ASPI</a>) reported quarterly losses of $(0.12) per share. This is a 25 percent increase over losses of $(0.16) per share from the same period last year. The company reported $1.10 million in sales this quarter. This is a 31.14 percent increase over sales of $840.35 thousand the same period last year.

ASPI

ASP Isotopes Q1 EPS $(0.12) Up From $(0.16) YoY, Sales $1.10M Up From $840.35K YoY

Society Pass (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOPA#NASDAQ">SOPA</a>) reported quarterly losses of $(0.44) per share which missed the analyst consensus estimate of $(0.20) by 120 percent. This is a 63.64 percent increase over losses of $(1.21) per share from the same period last year. The company reported quarterly sales of $1.47 million which missed the analyst consensus estimate of $2.20 million by 33.00 percent. This is a 20.19 percent decrease over sales of $1.85 million the same period last year.

Earnings Misses

SOPA

Society Pass Q1 EPS $(0.44) Misses $(0.20) Estimate, Sales $1.47M Miss $2.20M Estimate

Envirotech Vehicles (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVTV#NASDAQ">EVTV</a>) reported quarterly losses of $(0.18) per share. This is a 157.14 percent decrease over losses of $(0.07) per share from the same period last year. The company reported $590.57 thousand in sales this quarter. This is a 27.13 percent decrease over sales of $810.49 thousand the same period last year.

EVTV

Envirotech Vehicles Q1 Adj. EPS $(0.18) Down From $(0.07) YoY, Sales $590.57K Down From $810.49K YoY

WIIM

WOLF

Wolfspeed shares are trading lower amid reports that the company is preparing to file for bankruptcy within weeks.

Hedera Foundation CEO Charles Adkins said on Tuesday that integrating blockchain into social platforms will ensure transparent data handling and enable real‑time creator payments without centralized intermediaries.
In an interview with Benzinga, Adkins emphasized blockchain's capacity to enforce "trust and transparency" on social networks, particularly as governments introduce regulations requiring verifiable transaction histories and user‑data reporting.
"When regulatory regimes demand institutions submit transaction records or user data, a transparent, immutable ledger becomes essential," he said.
Adkins noted emerging privacy laws such as GDPR and forthcoming AI data‑protection rules will further elevate the need for cryptographically secured user consent and usage verification. "
You'll want to make sure your data is verified, used correctly and safeguarding consumers," he explained.
Asked about the U.S. regulatory landscape, Adkins welcomed recent clarity: "Regulation is moving in the right direction," he said, despite past governmental hesitancy over cryptocurrency's impact on fiat currencies. 
He observed that fear of undermining national currencies has slowed rule‑making but praised current momentum toward comprehensive guidelines.
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/25/05/45527096/bitcoin-whale-trader-up-over-20-million-in-unrealized-gains-on-700-million-btc-pepe-positions">Bitcoin Whale Trader Up Over $20 Million In Unrealized Gains On $700 Million BTC, Pepe Positions</a>
On blockchain's synergy with AI, Adkins argued that "AI actually pushes layer‑one blockchains to the forefront" by demanding provenance for training data and version control for evolving models. 
"Tokenizing each data input and embedding version control on‑chain ensures model integrity under future AI regulations," he said.
Addressing social media specifically, Adkins highlighted the unique fit of Hedera's low‑fee, deterministic‑finality Hashgraph: "Social platforms handle massive data flows and creator interactions requiring streaming micro‑payments. Only a predictable, fixed‑fee ledger can support real‑time tipping or content licensing at scale." 
He cited Hedera's participation in high‑profile TikTok acquisition bids as evidence of enterprise interest.
Adkins also touched on broader industry trends, noting that most new layer‑one chains lack sustainable use cases and that "general‑purpose blockchains launching today are often opportunistic rather than purposeful." 
He advocated industry‑wide standards, akin to early TCP/IP and HTTP protocols, to facilitate seamless cross‑chain interoperability and reduce "clunky" bridging.
Highlighting blockchain's transformative potential in developing economies: "Crypto and DeFi work best where ATMs don't. In volatile currencies, a stable token delivers predictability. For many users in South America, losing 10% of their paycheck daily, blockchain‑based stablecoins are life‑changing."
Read Next: • <a href="https://www.benzinga.com/markets/cryptocurrency/25/05/45526856/javier-milei-adjacent-meme-coin-no-longer-being-investigated-what-happened">Javier Milei-Adjacent Meme Coin No Longer Being Investigated: What Happened?</a>

Photo: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Fintech news covering the emerging Financial Technology services sector

Fintech

Social Media

Global

Exclusives

Hedera's Charles Adkins: Streaming Micro-Payments Could Transform How Creators Monetize Social Media

AMD stock has given up its prior gain. AMD shares were trading higher after Tesla CEO Elon Musk said Tesla expects to still buy GPUs from AMD and NVIDIA.

L3Harris Technologies Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LHX#NYSE">LHX</a>) shares are rising in extended trading Tuesday after the Trump administration announced plans for a Golden Dome missile defense system that will involve <a href="https://www.benzinga.com/25/05/45149289/golden-dome-fever-lockheed-raytheon-northrop-brace-for-a-missile-defense-windfall">the company&#8217;s satellites</a>.
What Happened: President Donald Trump on Tuesday <a href="https://www.whitehouse.gov/live/">announced</a> the architecture for a $175 billion Golden Dome missile defense system has been decided upon.
Trump announced that Gen. Michael Guetlein will oversee the program, which is expected to be completed in less than three years. Trump also said a budget package that&#8217;s currently in the works will include&nbsp;an initial $25 billion to begin construction of the project. 
Trump noted that the system will feature &#8220;next-generation technologies &#8230; including space-based sensors and interceptors.&#8221;&nbsp;
Trump did not name any companies specifically, but Sen. Jim Banks (R-Ind.) said that L3Harris will be involved in manufacturing space satellites for the defense system, which sent shares higher after hours. He added that &#8220;a lot&#8221; of American companies will be involved in the project.
Trump noted that the system will be made entirely in the U.S., with big contributions from Alaska, Georgia and Indiana. The Trump administration also noted that the project will include some &#8220;new, defense-tech companies.&#8221;
&#8220;Rest assured, there will be nothing like this. Nobody else is capable of building it either,&#8221; Trump said. 
LHX Price Action: <a href="http://benzinga.com/quote/lhx">L3Harris shares</a> were up 2.03% after-hours, trading at $235.50 at the time of publication on Tuesday, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/25/05/45483220/money-spigot-thats-never-going-off-meta-reportedly-hiring-ex-pentagon-officials-as-they-target-defense-contracts">&#8216;Money Spigot That&#8217;s Never Going Off&#8217;—Meta Reportedly Hiring Ex-Pentagon Officials As They Target Defense Contracts</a></li>
</ul>
Photo: Shutterstock.

Government

SPACE

After-Hours Center

Movers

L3Harris Stock Moves Higher After Being Named In 'Golden Dome' Missile Defense System

James Hardie Industries Q4 Adj. EPS $0.36, Inline, Sales $971.50M Miss $976.68M Estimate

Reborn Coffee (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REBN#NASDAQ">REBN</a>) reported quarterly losses of $(0.47) per share. This is a 21.67 percent increase over losses of $(0.60) per share from the same period last year. The company reported $1.69 million in sales this quarter. This is a 11.53 percent increase over sales of $1.52 million the same period last year.

REBN

Reborn Coffee Q1 EPS $(0.47) Up From $(0.60) YoY, Sales $1.69M Up From $1.52M YoY

OSR Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OSRH#NASDAQ">OSRH</a>) reported quarterly losses of $(1.04) per share. The company reported $761.27 million in sales this quarter.

OSRH

OSR Holdings Q1 EPS $(1.04), Sales $761.27M

Bank of New York Mellon (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BK#NYSE">BK</a>) has outperformed the market over the past 5 years by 4.89% on an annualized basis producing an average annual return of 19.55%. Currently, Bank of New York Mellon has a market capitalization of $64.46 billion. 
Buying $1000 In BK: If an investor had bought $1000 of BK stock 5 years ago, it would be worth $2,611.59 today based on a price of $90.10 for BK at the time of writing.
<h3>Bank of New York Mellon's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747776628_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

If You Invested $1000 In This Stock 5 Years Ago, You Would Have This Much Today

Toll Brothers Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TOL#NYSE">TOL</a>) released its second-quarter results after Tuesday's closing bell. Here's a look at the key figures <a href="https://www.benzinga.com/pressreleases/25/05/g45530143/toll-brothers-reports-fy-2025-second-quarter-results">from the quarter.</a>
The Details:&nbsp;Toll Brothers reported quarterly earnings of&nbsp;$3.50&nbsp;per share, which beat the analyst consensus estimate of&nbsp;$2.92&nbsp;by&nbsp;19.86%. Quarterly revenue came in at $2.71 billion,&nbsp;which beat the Street estimate of&nbsp;$2.48 billion. &nbsp;
Read Next: <a href="https://www.benzinga.com/news/large-cap/25/05/45524565/nvidias-1-trillion-comeback-shows-deepseek-no-longer-spooks-wall-street?utm_source=articleShare">Nvidia&#8217;s $1 Trillion Comeback Shows DeepSeek No Longer Spooks Wall Street&nbsp;</a>
For the second quarter, Toll Brothers reported: 
<ul class="wp-block-list">
<li>Home sales revenues were $2.71 billion, up 2% compared to last year&#8217;s second quarter; delivered homes were 2,899, up 10%.</li>
<li>Net signed contract value was $2.60 billion, down 11% compared to last year&#8217;s second quarter; contracted homes were 2,650, down 13%.</li>
<li>Backlog value was $6.84 billion at second quarter end, down 7% compared to last year&#8217;s second quarter; homes in backlog were 6,063, down 15%.</li>
<li>Adjusted home sales gross margin was 27.5%. </li>
</ul>
&#8220;We are pleased with our second quarter results, as we delivered earnings that significantly exceeded expectations. Despite a softer demand environment, we generated record second quarter home sales revenues of $2.71 billion, well above our guidance of $2.47 billion, and beat both our adjusted gross margin and SG&amp;A guidance,&#8221; said Douglas C. Yearley Jr., CEO of Toll Brothers.
TOL Price Action: According to data from <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Toll Brothers stock was up 4.79% at $109.52 after-hours on Tuesday.  
Read Next:&nbsp;
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/government/regulations/25/05/45506863/trumps-big-beautiful-bill-advances-heres-who-wins-and-loses?utm_source=articleShare">Trump&#8217;s &#8216;Big Beautiful Bill&#8217; Advances: Here&#8217;s Who Wins And Loses&nbsp;</a></li>
</ul>
Photo: Shutterstock

Real Estate

Toll Brothers Shares Are Up After Strong Q2 Results: EPS Beat, Revenues Beat

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) ("Teva") announced today that it successfully&nbsp;upsized its offering and priced approximately $2,300,000,000 (equivalent) of its senior notes (the "Notes"). The principal amount of the offering was increased from the previously announced offering size of $2,000,000,000 (equivalent). Teva expects to use the net proceeds from the offerings (i) to fund the announced tender offers (collectively, the "Tender Offer") to purchase, for cash, its 3.150% Senior Notes due 2026, 4.750% Sustainability-Linked Senior Notes due 2027, 3.750% Sustainability-Linked Senior Notes due 2027, 7.875% Sustainability-Linked Senior Notes due 2029, 7.375% Sustainability-Linked Senior Notes due 2029 and 8.125% Sustainability-Linked Senior Notes due 2031&nbsp;(as it may be amended prior to expiration thereof), (ii) to pay fees and expenses in connection therewith and (iii) to the extent of any remaining proceeds, the repayment of outstanding debt upon maturity, tender offer or earlier redemption. Net proceeds may be temporarily invested pending application for their stated purpose.
The Notes consist of (i) Teva Pharmaceutical Finance Netherlands II B.V's ("Teva Finance II") €1,000,000,000 aggregate principal amount of 4.125% EUR-denominated Senior Notes maturing in 2031, (ii) Teva Pharmaceutical Finance Netherlands III B.V.'s ("Teva Finance III") $500,000,000 aggregate principal amount of 6.000% USD-denominated Senior Notes maturing in 2032 and (iii) Teva Pharmaceutical Finance Netherlands IV B.V.'s ("Teva Finance IV" and, together with Teva Finance II and Teva Finance III, the "Issuers") $700,000,000 aggregate principal amount of 5.750% USD-denominated Senior Notes maturing in 2030.
The settlement of the Notes is expected to occur on or about May 28, 2025, subject to customary closing conditions. The settlement of the Notes will satisfy the financing condition to the Tender Offer.

Offerings

TEVA

Teva Pharmaceutical Industries Announces It Upsized Its Offering From $2B And Priced ~$2.3B Of Its Senior Notes

OSUR

Orasure Technologies Files For Mixed Shelf Of Up To $300M

General

Equus Total Return Receives NYSE Notice Of Non-Compliance With Minimum Share Price Requirement

Deupirfenidone 825 mg TID slowed lung function decline in people with idiopathic pulmonary fibrosis (IPF) to the range expected of healthy older adults over 6 months; new, preliminary open-label extension data support durability of this treatment effect over at least 52 weeks
Deupirfenidone 825 mg TID demonstrated a statistically significant benefit compared to placebo in delaying IPF progression
Detailed safety analysis underscores favorable tolerability profile for deupirfenidone
PureTech plans to meet with FDA before end of Q3 2025, with the goal of initiating a Phase 3 trial by year-end
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fpuretechhealth.com%2F&amp;esheet=54257865&amp;newsitemid=20250520345638&amp;lan=en-US&amp;anchor=PureTech+Health+plc&amp;index=1&amp;md5=d3c41ff08eb102e88d128b2fd110bddc">PureTech Health plc</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTC#NASDAQ">PRTC</a>, LSE: PRTC))) (&quot;PureTech&quot; or the &quot;Company&quot;), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, delivered a late-breaking, oral presentation at the 2025 American Thoracic Society (ATS) International Conference in San Francisco. The presentation provided further insights into the <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fnews.puretechhealth.com%2Fnews-releases%2Fnews-release-details%2Fpuretechs-deupirfenidone-lyt-100-slowed-lung-function-decline&amp;esheet=54257865&amp;newsitemid=20250520345638&amp;lan=en-US&amp;anchor=successful+Phase+2b+ELEVATE+IPF+trial&amp;index=2&amp;md5=df2f852b2e4793a012c9f61e73a222f2">successful Phase 2b ELEVATE IPF trial</a> of deupirfenidone (LYT-100), highlighting the strength and durability of deupirfenidone&#39;s treatment effect through at least 52 weeks while maintaining favorable tolerability in patients living with idiopathic pulmonary fibrosis (IPF).

Biotech

PRTC

PureTech Presents Phase 2b Data For Deupirfenidone At ATS 2025, Showing Statistically Significant Slowing Of IPF Progression With Durable Effect Over 52 Weeks, Favorable Safety Profile, And Plans For FDA Meeting And Phase 3 Trial Launch By End Of 2025

Press Releases

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Fortrea Holdings Inc. - FTRE

Fortrea Announces Date for First Quarter 2025 Financial Results and Conference Call

Legal

Fortrea Named a Leader in Everest Group's Pharmacovigilance Operations PEAK Matrix® Assessment 2025

Management

Fortrea Announces CEO Stepping Down

Fortrea Reports First Quarter 2025 Results

Small Cap

Securities Fraud Investigation Into Fortrea Holdings Inc. (FTRE) Continues – Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz

Fortrea Holdings Inc. (FTRE) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation

Securities Fraud Investigation Into Fortrea Holdings Inc. (FTRE) Continues – Investors Who Lost Money Urged to Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm

AbCellera Biologics

Adaptive Biotechnologies Corporation - Common Stock

Adaptive Biotechnologies

Atlantic International Corp. - Common Stock

Atlantic International

Azenta

BioLife Solutions

Bruker

Codexis

Cytek Biosciences

CryoPort

Evotec SE - American Depositary Shares each representing 1/2 of one ordinary share

Comments

Fortrea Holdings

Notizie

Ultime notizie per Fortrea Holdings (NASDAQ:FTRE) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO